2013

Backed

by HTGF since

OMEICOS

Invested since 2013
Based in Berlin

About the company

OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.

Do you want to

know more about this company?

Zum Artikel

Ulrike Kalapis Investment Manager

Ulrike KalapisInvestment Manager

More startups from Life Sciences